Compare Rush Street Interactive Inc (RSI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rush Street Interactive Inc vs Recursion Pharmaceuticals Inc — how do they compare? Rush Street Interactive Inc trades at $20.26 (market cap $2.35B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: Rush Street Interactive Inc and Recursion Pharmaceuticals Inc are close in size by market cap, and Recursion Pharmaceuticals Inc is more actively traded (30,789,535 versus 2,219,374). Which is the better fit depends on your goals — on Pluang, investors hold Rush Street Interactive Inc for 13 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| RSI | RXRX | |
|---|---|---|
Market Cap | $2.35B | $2.14B |
Volume | 2,219,374 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.52 | $6.79 |
52-Week Low | $15.89 | $2.84 |
Typical Hold Time | 13 Days | 22 Days |
Enterprise Value | $2.01B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RSI trades at $20.24, down 1.56% with bearish technical signals but strong analyst support. The company shows revenue growth from $1.13B in 2025 to $1.4B projected for 2026, though net income margin compressed from 2.93% to 2.33%. Recent Q2 2026 earnings beat expectations with $0.15 EPS versus $0.1499 expected. Technical indicators show mixed signals with moving averages bearish but oscillators neutral, while institutional activity includes BlackRock's $448M investment in August 2026.
The stock presents a compelling valuation gap with consensus price target of $34.88 representing 72% upside, supported by 77% buy ratings from analysts. Key risks include competitive pressures in online gaming and margin compression despite revenue growth. The company's participation in major industry conferences and strong institutional backing provides fundamental support for long-term growth prospects.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
